Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
NCT07652905Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in plasma cell leukaemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2026; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on NCT07652905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652905.